Christelle Lévy

10.1k total citations · 3 hit papers
139 papers, 3.1k citations indexed

About

Christelle Lévy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Christelle Lévy has authored 139 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Oncology, 77 papers in Pulmonary and Respiratory Medicine and 63 papers in Cancer Research. Recurrent topics in Christelle Lévy's work include Breast Cancer Treatment Studies (52 papers), Cancer Treatment and Pharmacology (49 papers) and Advanced Breast Cancer Therapies (42 papers). Christelle Lévy is often cited by papers focused on Breast Cancer Treatment Studies (52 papers), Cancer Treatment and Pharmacology (49 papers) and Advanced Breast Cancer Therapies (42 papers). Christelle Lévy collaborates with scholars based in France, Luxembourg and United States. Christelle Lévy's co-authors include Gϋnter von Minckwitz, José Bines, Richard D. Gelber, Martine Piccart, Emma Clark, István Láng, Adam Knott, Evandro de Azambuja, Amal Arahmani and Dimitrios Zardavas and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Christelle Lévy

131 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

2017 918 citations Christelle Lévy et al. profile →
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

2024 144 citations Aditya Bardia, Rebecca Dent et al. profile →
Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).

2024 52 citations Giuseppe Curigliano, Xichun Hu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Christelle Lévy

Since Specialization

Citations

This map shows the geographic impact of Christelle Lévy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christelle Lévy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christelle Lévy more than expected).

Fields of papers citing papers by Christelle Lévy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christelle Lévy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christelle Lévy. The network helps show where Christelle Lévy may publish in the future.

Co-authorship network of co-authors of Christelle Lévy

This figure shows the co-authorship network connecting the top 25 collaborators of Christelle Lévy. A scholar is included among the top collaborators of Christelle Lévy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christelle Lévy. Christelle Lévy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	299MO DESTINY-Breast06 (DB-06) post-hoc analysis by physician’s choice of chemotherapy (TPC): Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs TPC in hormone receptor–positive (HR+), HER2-low or -ultralow metastatic breast cancer (mBC) 2025 ·ESMO Open ·Carlos H. Barrios, Aditya Bardia, Xin Hu, Rebecca Dent, Kan Yonemori, J-Y Pierga, Laura Biganzoli, Christelle Lévy, S-A. Im, Juntao Ke, (unknown), (unknown), Giuseppe Curigliano	1
2	Sleep oscillations related to memory consolidation during aromatases inhibitors for breast cancer 2024 ·Sleep Medicine ·Stéphane Rehel, (unknown), (unknown), (unknown), Patrice Clochon, Jean‐Michel Grellard, (unknown), Julien Geffrelot, George Emile, Djelila Allouache, Christelle Lévy, Fausto Viader, Florence Eustache, Florence Joly, Bénédicte Giffard, Joy Perrier	1
3	Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). breakdown → 2024 ·Journal of Clinical Oncology ·Giuseppe Curigliano, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Qingyuan Zhang, Seock‐Ah Im, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Christelle Lévy, William Jacot, (unknown), Jun Ke, Gargi Patel, Aditya Bardia	52
4	Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohort 2024 ·ESMO Open ·Nicolas Epaillard, Amélie Lusque, William Jacot, Audrey Mailliez, Thomas Bachelot, Mónica Arnedos, Fanny Le Du, Étienne Brain, Jean-Marc Ferrero, (unknown), Isabelle Desmoulins, M-A Mouret-Reynier, Christelle Lévy, A. Gonçalves, (unknown), Thierry Petit, Thomas Filleron, L. Bosquet, Barbara Pistilli, Jean‐Sébastien Frenel	3
5	LBA22 Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06 2024 ·Annals of Oncology ·(unknown), G. Curigliano, Kan Yonemori, (unknown), Carlos H. Barrios, (unknown), Christelle Lévy, William Jacot, (unknown), (unknown), Aude Roborel de Climens, Xiaojian Wu, (unknown), (unknown), Rebecca Dent	1
6	Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors 2023 ·Frontiers in Oncology ·(unknown), George Emile, Alison Johnson, Christelle Lévy, Djelila Allouache, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Justine Lequesne, Angélique Da Silva	10
7	Baseline quality of life and chemotherapy toxicities in patients with early breast cancer 2023 ·Cancer ·Idlir Licaj, Elodie Coquan, Tienhan Sandrine Dabakuyo‐Yonli, Sarah Dauchy, Inês Vaz-Luís, Cécile Charles, Cédric Lemogne, Olivier Trédan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Lévy, Olivier Rigal, Marion Fournier, Thierry Petit, Florence Dalenc, Philippe Rouanet, Jérôme Lemonnier, Sibille Everhard, Paul Cottu, Florence Joly	4
8	Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation 2023 ·British Journal of Cancer ·Jean‐Sébastien Frenel, Amélie Lusque, Suzette Delaloge, J-M Ferrero, Thomas Bachelot, Isabelle Desmoulins, Christelle Lévy, J.C. Eymard, Anthony Gonçalvès, Anne Patsouris, (unknown), (unknown), Thierry Petit, Luc Cabel, L. Uwer, Marc Debled, M. Chevrot, Audrey Mailliez, William Jacot, Thibault De La Motte Rouge	3
9	Self‐referential processes and resting‐state connectivity in breast cancer patients before and 1 year after chemotherapy 2022 ·European Journal of Neuroscience ·Joy Perrier, (unknown), Béatrice Desgranges, Djelila Allouache, Christelle Lévy, Sabine Noal, Jacques Dayan, Francis Eustache, Florence Joly, Armelle Viard, Bénédicte Giffard	3
10	First Combined Study on Lorentz Invariance Violation from Observations of Energy-dependent Time Delays from Multiple-type Gamma-Ray Sources. I. Motivation, Method Description, and Validation through Simulations of H.E.S.S., MAGIC, and VERITAS Data Sets 2022 ·The Astrophysical Journal ·J. Bolmont, Sami Caroff, M. Gaug, A. Gent, (unknown), D. Kerszberg, Christelle Lévy, (unknown), M. Martı́nez, L. Nogués, A. N. Otte, C. Perennes, Michele Ronco, T. Terzić	16
11	Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study 2022 ·Molecular Oncology ·Renaud Sabatier, Cécile Vicier, Séverine Garnier, Arnaud Guillé, Nadine Carbuccia, Nicolás Isambert, Florence Dalenc, Marie Robert, Christelle Lévy, Jihane Pakradouni, José Adélaı̈de, Max Chaffanet, (unknown), Émilie Mamessier, François Bertucci, Anthony Gonçalvès	5
12	Different Prognostic Values of Tumour and Nodal Response to Neoadjuvant Chemotherapy Depending on Subtypes of Inflammatory Breast Cancer, a 317 Patient-Study 2022 ·Cancers ·(unknown), Julia Salleron, Youlia Kirova, (unknown), (unknown), Christelle Lévy, Marianne Leheurteur, (unknown), Eleonor Rivin del Campo, (unknown), (unknown), (unknown), Juliette Thariat, S. Thureau	6
13	HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer 2022 ·BMC Cancer ·(unknown), Angélique Da Silva, Alison Johnson, Cécile Blanc‐Fournier, (unknown), (unknown), Christelle Lévy, Djelila Allouache, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Justine Lequesne, George Emile	12
14	Étude en vie réelle de la survie à 7 ans des patientes traitées avec trastuzumab pour un cancer du sein précoce HER2+ 2020 ·Bulletin du Cancer ·Mahasti Saghatchian, Elsa Curtit, David Coeffic, Alain Flinois, Christelle Lévy	1
15	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer 2020 ·Frontiers in Oncology ·(unknown), François Bertucci, Christophe Zemmour, Florence Lerebours, Jean‐Yves Pierga, Christelle Lévy, Florence Dalenc, Julien Grenier, Thierry Petit, (unknown), Anthony Gonçalvès	7
16	Association between FGFR1 copy numbers, MAP3K1 mutations, and survival in axillary node-positive, hormone receptor-positive, and HER2-negative early breast cancer in the PACS04 and METABRIC studies 2019 ·Breast Cancer Research and Treatment ·(unknown), Alicia Tran-Dien, Jérôme Lemonnier, Florence Dalenc, Christelle Lévy, Jean‐Yves Pierga, William Jacot, Jean-Luc Canon, Catherine Richon, Ludovic Lacroix, Christophe Caux, Fabrice André, Stefan Michiels	10
17	Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations 2016 ·Cancer Research ·Yu Fu, Cécile Jovelet, Thomas Filleron, Marion Pedrero, Nelly Motté, Yannick Boursin, (unknown), Christophe Massard, Mario Campone, Christelle Lévy, Véronique Dièras, Thomas Bachelot, Julie Garrabey, Jean‐Charles Soria, Ludovic Lacroix, Fabrice André, Céline Lefèbvre	11
18	Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases 2016 ·Breast Cancer Research and Treatment ·William Jacot, Elvire Pons‐Tostivint, Jean‐Sébastien Frenel, Séverine Guiu, Christelle Lévy, Pierre-Étienne Heudel, Thomas Bachelot, Véronique D’Hondt, Amélie Darlix, Nelly Firmin, Gilles Romieu, Simon Thézenas, Florence Dalenc	79
19	Inflammatory breast cancer outcome with epirubicin‐based induction and maintenance chemotherapy 2006 ·Cancer ·Corinne Veyret, Christelle Lévy, P. Chollet, Yacine Merrouche, Henri Roché, Pierre Kerbrat, P. Fumoleau, P. Fargeot, P. Clavère, Bernard Chevallier	27
20	Expression quantitative de la couleur dans la serie tennantite-tetraedrite; influence des substitutions 1982 ·The Canadian Mineralogist ·(unknown), Christelle Lévy	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact